Gilgamesh’s short-acting psychedelic drug shows rapid effect in Phase 2 depression study

Max Bayer

Pharma Reporter

Gilgamesh’s drug showed swift and durable effects as a treatment for major depressive disorder in a mid-stage study, demonstrating promising results for one of the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Gilgamesh’s short-acting psychedelic drug shows rapid effect in Phase 2 depression study

Max Bayer

Pharma Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

A new dawn for psychedelics? Compass could be the first to find out

Updated: MD Anderson-allied investment firm targets $250M for second cancer biotech fund

Weeks after TIGIT fail, iTeos decides to wind down

Strand Therapeutics reports promising start for mRNA cancer therapy

Novartis won bidding war for kidney drug as Regulus' top three execs expect to make over $100M combined

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Gil­gamesh’s short-act­ing psy­che­del­ic drug shows rapid ef­fect in Phase 2 de­pres­sion study

Pharma Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Gilgamesh’s short-acting psychedelic drug shows rapid effect in Phase 2 depression study